Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 29, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Triple-negative breast cancer.

Gert Stockmans1, Karen Deraedt, Hans Wildiers

  • 1Department of Internal Medicine, University Hospital Gasthuisberg, Herestraat, Leuven, Belgium.

Current Opinion in Oncology
|October 9, 2008
PubMed
Summary

Triple-negative breast cancer (TNBC) research reveals its complex subtypes and poor prognosis. New targeted therapies, particularly receptor kinase inhibitors, show promise but require further clinical validation.

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026
Same author

Effectiveness of comprehensive geriatric assessment with patient coaching on toxicity, premature treatment interruption, unplanned hospitalisations, and survival in older patients with solid tumours: Secondary endpoints of the G-oncoCOACH study.

Journal of geriatric oncology·2026
Same author

Cardiovascular event burden in women with breast cancer treated with CDK4/6 inhibitors: a retrospective matched cohort study.

Cardio-oncology (London, England)·2026
Same author

De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world study.

Breast (Edinburgh, Scotland)·2026
Same author

Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

The association between parity, age of first full term pregnancy and invasive lobular breast cancer: a case-only analysis.

Cancer treatment and research communications·2026

Area of Science:

  • Oncology
  • Pathology
  • Genetics

Background:

  • Triple-negative breast cancer (TNBC) lacks targeted therapies like hormonal or HER2-targeted treatments.
  • Chemotherapy is the sole systemic option, with limited efficacy and poor patient outcomes.
  • TNBC is a clinically and pathologically heterogeneous cancer subgroup.

Purpose of the Study:

  • To review recent pathological and genetic advancements in TNBC.
  • To explore the implications of these advances for developing novel treatment strategies.

Main Methods:

  • Review of current oncological literature.
  • Analysis of pathological and molecular data in TNBC.
  • Evaluation of emerging targeted therapies.

Related Experiment Videos

Last Updated: Jun 29, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Main Results:

  • Advances in understanding breast cancer have highlighted TNBC's heterogeneity.
  • Subtyping TNBC remains challenging, hindering precise treatment selection.
  • Novel targeted therapies, including receptor kinase inhibitors, are under investigation.

Conclusions:

  • Recent molecular and pathological insights have reshaped breast cancer understanding, identifying TNBC as a diverse group.
  • Developing tailored treatments for distinct TNBC subgroups is a critical challenge.
  • Receptor kinase inhibition represents a promising therapeutic avenue, pending further clinical validation.